Boston Scientific Corporation
BSX
$73.85
-$2.37-3.11%
NYSE
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
EPS (TTM)
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.29B | 5.07B | 5.06B | 4.66B | 4.56B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.29B | 5.07B | 5.06B | 4.66B | 4.56B |
| Cost of Revenue | 1.61B | 1.54B | 1.65B | 1.47B | 1.48B |
| Gross Profit | 3.67B | 3.53B | 3.41B | 3.20B | 3.09B |
| SG&A Expenses | 1.83B | 1.74B | 1.72B | 1.60B | 1.61B |
| Depreciation & Amortization | 228.00M | 225.00M | 225.00M | 219.00M | 225.00M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.25B | 4.02B | 4.12B | 3.73B | 3.77B |
| Operating Income | 1.04B | 1.05B | 943.00M | 937.00M | 790.00M |
| Income Before Tax | 700.00M | 938.00M | 941.00M | 805.00M | 584.00M |
| Income Tax Expenses | 30.00M | 183.00M | 146.00M | 133.00M | 23.00M |
| Earnings from Continuing Operations | 670.00M | 755.00M | 795.00M | 672.00M | 561.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 2.00M | -- | 2.00M | 2.00M | 4.00M |
| Net Income | 672.00M | 755.00M | 797.00M | 674.00M | 565.00M |
| EBIT | 1.04B | 1.05B | 943.00M | 937.00M | 790.00M |
| EBITDA | 1.41B | 1.39B | 1.28B | 1.26B | 1.14B |
| EPS Basic | 0.45 | 0.51 | 0.54 | 0.46 | 0.38 |
| Normalized Basic EPS | 0.43 | 0.39 | 0.55 | 0.35 | 0.32 |
| EPS Diluted | 0.45 | 0.51 | 0.53 | 0.45 | 0.38 |
| Normalized Diluted EPS | 0.42 | 0.39 | 0.54 | 0.35 | 0.32 |
| Average Basic Shares Outstanding | 1.48B | 1.48B | 1.48B | 1.48B | 1.47B |
| Average Diluted Shares Outstanding | 1.50B | 1.50B | 1.49B | 1.49B | 1.49B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |